FDA Mulls Renaming Rockfish: Fishermen, Weigh In on Labels!
Published Date: 4/1/2026
Notice
Summary
The FDA wants to hear from fishermen, seafood sellers, and fish lovers about possibly changing the official market names for certain rockfish species. This update aims to make fish labels clearer and safer for everyone, with comments open until May 1, 2026. If the name changes happen, it could affect how these fish are sold and marketed, so your input matters!
Analyzed Economic Effects
6 provisions identified: 0 benefits, 4 costs, 2 mixed.
Different Species, Different Food Hazards
FDA notes rockfish (Sebastes spp.) have parasite risks that require cooking or freezing, while some species called "snapper" carry ciguatera toxin risks—mixing names could cause processors to apply the wrong hazard controls and potentially harm consumers. FDA is seeking comments on how to avoid food safety risks if names change.
Allergen Labeling Risk from Name Changes
Finfish are a major food allergen and the law requires the specific fish be identified by its common or usual name on labels (sections 201(qq) and 403(w) of the FD&C Act). FDA warns that changing the acceptable market name for rockfish could cause allergic consumers to inadvertently eat rockfish if labels use a different name, and it reminds manufacturers they must still comply with allergen labeling rules.
FDA Reviewing Rockfish Market Names
The FDA is considering changing the official market name for 18 Sebastes (rockfish) species after Congress directed review in Public Law 119-37, Section 777 (enacted November 2025). FDA is asking for data and public comment on potential new names and related guidance, with comments due May 1, 2026.
Name Change Could Alter Market Value
Industry stakeholders have requested switching some rockfish names to terms like "snapper" to increase economic value, and FDA is asking for data on economic impacts if rockfish were labeled with another species' market name or a new name. FDA specifically requests evidence about economic or other impacts of any name change.
Labeling and HACCP Compliance Costs
FDA asks how changes to the acceptable market name for rockfish would affect Hazard Analysis and Critical Control Point (HACCP) plans, labeling, and recordkeeping and requests estimated compliance costs for industry to update these systems. If names change, processors and sellers may need to revise HACCP plans and labels, which could require time and expense.
Current Misbranding Rules and Legal Risk
Under current FDA policy, labeling Sebastes species as "snapper" in interstate commerce would be considered false or misleading and misbranded under section 403(a)(1) of the FD&C Act; FDA also treats only Lutjanus campechanus as lawful to sell as "red snapper." Any name change could require updates to The Seafood List and prohibited vernacular names.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-06293 — Non-Refillable Steel Cylinders From China; Institution of Five-Year Reviews
The U.S. is checking if special taxes on non-refillable steel cylinders from China should stay or go. This affects companies that make or sell these cylinders and could impact prices or jobs. If you’re interested, you’ve got until May 1, 2026, to share your thoughts, so don’t miss out!
Next: 2026-06297 — Implementing Section 927 Waiver Process for Certain Unmanned Aircraft Operations
The FAA is rolling out a new waiver process to help drone operators fly in ways that don’t fit current rules. This change makes it easier and faster for certain unmanned aircraft to get permission without jumping through complicated hoops. Starting now, affected drone pilots can apply for these waivers, saving time and possibly money while keeping the skies safe.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in